Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075398 | 0.99 | CYP1A2 (0.32) | CYP1A2L3MBTL1CASP3MAPT | |
| SCHEMBL2076072 | 0.94 | CASP3 (0.33) | ALDH1A1L3MBTL1CASP3MAPT | |
| SCHEMBL2077880 | 0.88 | CASP3 (0.34) | ALDH1A1L3MBTL1CASP3MAPT | |
| SCHEMBL2075078 | 0.82 | CASP3 (0.36) | ALDH1A1L3MBTL1CASP3MAPT | |
| SCHEMBL2075841 | 0.79 | ALOX5 (0.32) | — | |
| SCHEMBL2078236 | 0.77 | ALOX5 (0.30) | — | |
| SCHEMBL2076501 | 0.76 | MAPT (0.40) | ALDH1A1L3MBTL1CASP3KDM4EHTT | |
| SCHEMBL2075051 | 0.75 | MEN1 (0.43) | ALDH1A1L3MBTL1CASP3MAPT | |
| SCHEMBL2077443 | 0.73 | CASP3 (0.30) | CASP3 | |
| SCHEMBL2076902 | 0.72 | CASP3 (0.33) | ALDH1A1L3MBTL1CASP3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2028183-B1 | NOVEL EPOXY COMPOUND AND METHOD FOR PRODUCING THE SAME | SHOWA DENKO KK (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-7863461-B2 | Epoxy compounds and method for production of the same | SHOWA DENKO K.K. (JP) | 2011-01-04 | — | — | US | disclosed |
| US-20090253915-A1 | NOVEL EPOXY COMPOUNDS AND METHOD FOR PRODUCTION OF THE SAME | SHOWA DENKO K.K. (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2028183-A1 | NOVEL EPOXY COMPOUND AND METHOD FOR PRODUCING THE SAME | Showa Denko K.K. (JP) | 2009-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253915-A1 | NOVEL EPOXY COMPOUNDS AND METHOD FOR PRODUCTION OF THE SAME | PTGIS, PTGES, CYP2E1 | CYP1A2 79/4885ALDH1A1 607/4885L3MBTL1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.